Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Creative Medical Technology Holdings (CELZ) Cost of Revenue (2017 - 2025)

Creative Medical Technology Holdings (CELZ) has disclosed Cost of Revenue for 9 consecutive years, with $1200.0 as the latest value for Q1 2025.

  • On a quarterly basis, Cost of Revenue changed N/A to $1200.0 in Q1 2025 year-over-year; TTM through Sep 2025 was $2400.0, a 45.45% decrease, with the full-year FY2024 number at $4400.0, up 22.22% from a year prior.
  • Cost of Revenue was $1200.0 for Q1 2025 at Creative Medical Technology Holdings, roughly flat from $1200.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $39449.0 in Q4 2021 to a low of $1200.0 in Q4 2023.
  • A 5-year average of $7785.5 and a median of $4000.0 in 2021 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: soared 393.11% in 2021, then plummeted 85.55% in 2022.
  • Creative Medical Technology Holdings' Cost of Revenue stood at $39449.0 in 2021, then tumbled by 85.55% to $5700.0 in 2022, then crashed by 78.95% to $1200.0 in 2023, then changed by 0.0% to $1200.0 in 2024, then changed by 0.0% to $1200.0 in 2025.
  • Per Business Quant, the three most recent readings for CELZ's Cost of Revenue are $1200.0 (Q1 2025), $1200.0 (Q4 2024), and $3200.0 (Q2 2024).